Participated · Series A · Jun 2026

FesariusTherapeutics is a commercial-stage medical technology company headquartered in New York whose flagship product, DermiSphere™, is the first hydrogel Dermal Regeneration Template (hDRT) cleared by the FDA (510(k) clearance in January 2025). DermiSphere™ features a patented dual-density collagen microarchitecture intended to facilitate cellular integration and vascularization to support wound healing. The device is commercially active across multiple U.S. hospital systems and the company reports growing clinical momentum. Fesarius plans to pursue Breakthrough Device Designation, expanded reimbursement pathways, and a pivotal clinical trial supporting a OneStep procedure and future label expansion. The company will use proceeds from its $20 million Series A to accelerate commercial infrastructure and expand its national direct sales coverage. The financing included strategic and institutional investors, signaling validation from both corporate and specialty-society backers.

Participated · Seed · Feb 2026

Entirety Biomedical is a Michigan-based medical device startup creating absorbable metal implants that offer titanium-like strength during healing and then safely resorb once bone union is achieved. Its patented Curasorb alloy underpins plate-and-screw and headless compression screw systems aimed initially at lower-extremity and maxillofacial procedures, allowing surgeons to avoid permanent hardware without changing existing surgical workflows or reimbursement models. The company completed its first preclinical study in 2024 and is running three additional preclinical studies, with early data showing strong osseointegration. These studies will guide a planned first-in-human clinical trial of its lower-extremity headless compression screw system. Entirety works closely with surgeons and strategic partners to identify unmet fixation needs and translate them into products that improve patient outcomes and reduce secondary removal surgeries. Founded by materials-science engineers Jake Edick and Carolyn Woldring, the team brings more than a decade of absorbable magnesium R&D experience and multiple related patents. The startup recently secured $1.2 million in seed funding to advance product development toward clinical trials.